Collaborative Arrangements and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2023

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):

	Three Months Ended March 31,
	2023			2022
SPINRAZA royalties (commercial revenue)	$	50,247		$	53,818
R&D revenue		20,254			40,049
Total revenue from our relationship with Biogen	$	70,501		$	93,867
Percentage of total revenue		54	%		66	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentage amounts):

	Three Months Ended March 31,
	2023			2022
R&D revenue	$	15,000		$	—
Percentage of total revenue		11	%		—